News
Drug and biotech news
Last checked: Nov 20, 2026Source: BioPharma Dive, STAT (pharma), FDA press releases, FDA MedWatch, Drugs@FDA (new approvals), openFDA (Class I recalls)
7 stories
Tagged Oncology from the headline and teaser, so some stories may be missed or misfiled.
- Trade pressBioPharma DiveNov 20, 2026Erasca data add to pressure facing Revolution’s breakthrough cancer drug
Rasonque is already off to one of the best oncology launches in history. But certain limitations leave an opportunity that companies like Erasca - which is nearing the start of a Phase 3 trial - may be able to exploit.
- Trade pressSTAT (pharma)Nov 20, 2026STAT+: Pharmalittle: We're reading about Sanofi eyeing Insmed, AI speeding drug development, and more
Sanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:
- Trade pressSTAT (pharma)Nov 20, 2026STAT+: Early results for Alterome's KRAS drug for pancreas, lung and colon cancer arrive
Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon:
- Trade pressBioPharma DiveNov 20, 2026Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
Wall Street analysts rushed to Celldex's defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva's research chief accepted a new job.
- Trade pressSTAT (pharma)Nov 18, 2026STAT+: FDA discloses reasons for rejecting Summit drug
The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
- Trade pressSTAT (pharma)Nov 17, 2026STAT+: Pharmalittle: We're reading about a Roche breast cancer pill, obesity drugs in children, and more
The FDA approved a breast cancer drug from Roche, teeing up the launch of what the company has said could become its top-selling product
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
The FDA approved a new breast cancer drug from Roche, teeing up the launch of a medicine the company has said could become its top-selling product ever.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.